The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in
the past few years, driven largely by translational research into its genomic landscape and …

The effective treatment of acute myeloid leukemia (AML) is very challenging. Due to the
immense heterogeneity of this disease, treating it using a “one size fits all” approach is …

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that
has a poor prognosis. Recent advances in genomics and molecular biology have led to a …

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with an
incidence that increases with age, and a generally poor prognosis. The disease is clinically …

Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous disease.
Despite advances in understanding the pathogenesis of AML, the standard therapy …

In the past few years, research in the underlying pathogenic mechanisms of acute myeloid
leukaemia (AML) has led to remarkable advances in our understanding of the disease …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …

Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …

Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options,
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …

The standard therapy for acute myeloid leukemia (AML) has not changed meaningfully for
the past four decades. Improvements in supportive care and modifications to the dose and …